Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue

Below are the small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of revenue. The trailing-twelve-month revenue at Neogen

is $225.21 million. Neogen's ROE for the same period is 10.59%. The trailing-twelve-month revenue at Abaxis

is $188.77 million. Abaxis's PEG ratio is 5.40. The trailing-twelve-month revenue at Meridian Bioscience

is $188.13 million. Meridian Bioscience's operating margin for the same period is 29.69%. The trailing-twelve-month revenue at Quidel

is $177.66 million. Quidel's EPS for the same period is $0.42.